Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled

Phathom Pharmaceuticals, Inc.

2025-Q2 EPS reported -$2.36 revenue$68,023,000

Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.
Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).
10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.
Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.
Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.